AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31797578 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 52
Study 31797578 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 450 mg
Number of subjects: 52
Study 31797578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31797578 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52
Study 30001701 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP-Family intervention (includes a one-day workshop for parents and children, psychological exercises based on the Fun FRIENDS protocol, sports exercises, and a follow-up session 4 weeks later)
Number of subjects: 0
Study 30001701 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (no psychosocial intervention)
Number of subjects: 0
Study 27538157 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 40
Study 27538157 — intervention group
Group type: COMPARATOR
Intervention: Common equipment (dental elevators, chisels, forceps)
Number of subjects: 40
Study 24936902 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive-overload whole-body vibration training (WBV)
Number of subjects: 18
Study 22700666 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 110
Study 22700666 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 110
Study 20368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wound care with > or = 50% percent area reduction (PAR) at week 4
Number of subjects: 142
Study 20368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wound care with < 50% percent area reduction (PAR) at week 4
Number of subjects: 142
Study 20368673 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care regardless of baseline size category
Number of subjects: 142
Study 18578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling intervention (10 sessions)
Number of subjects: 1044
Study 18578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling intervention
Number of subjects: 1044
Study 18578875 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1044
Study 16041547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg daily (n=6)
Number of subjects: 12
Study 16041547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily (n=6)
Number of subjects: 12
Study 12366605 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care programme (SCP)
Number of subjects: 875
Study 12366605 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 875
Study 10375366 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 34-35 weeks
Number of subjects: 62
Study 10375366 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at 38-40 weeks
Number of subjects: 62
Study 7748680 — intervention group
Group type: EXPERIMENTAL
Intervention: BiliBlanket phototherapy
Number of subjects: 44
Study 7748680 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 44
Study 2405456 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (SD) restricted to the 2 hours between 3:00 and 5:00 in the morning
Number of subjects: 33
Study 2405456 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (SD)
Number of subjects: 33
Study 2405456 — intervention group
Group type: COMPARATOR
Intervention: No sleep deprivation (undisturbed sleep)
Number of subjects: 33
Study 6778197 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 120 mg/day
Number of subjects: 13
Study 6778197 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 240 mg/day
Number of subjects: 13
Study 6778197 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 13
Study 31809409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExDEF (exercise energy deficit)
Number of subjects: 15
Study 31809409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExBAL (exercise energy balance)
Number of subjects: 15
Study 31809409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExDEF
Number of subjects: 15
Study 31809409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExBAL
Number of subjects: 15
Study 31809409 — intervention group
Group type: COMPARATOR
Intervention: NoEx (nonexercise control)
Number of subjects: 15
Study 31815653 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course systemic antibiotics (≤ 7 days)
Number of subjects: 0
Study 31815653 — intervention group
Group type: COMPARATOR
Intervention: Long course systemic antibiotics (≥ 4 weeks)
Number of subjects: 0
Study 27864471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch Is in the Bag intervention
Number of subjects: 633
Study 27864471 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 633
Study 25315169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 40
Study 25315169 — intervention group
Group type: COMPARATOR
Intervention: Pubovaginal sling (PVS)
Number of subjects: 40
Study 23575759 — intervention group
Group type: EXPERIMENTAL
Intervention: Blake drain (silastic tube), removed on postoperative day (POD) 5
Number of subjects: 150
Study 23575759 — intervention group
Group type: COMPARATOR
Intervention: Conventional mediastinal tube, removed on POD 1
Number of subjects: 150
Study 23575759 — intervention group
Group type: EXPERIMENTAL
Intervention: Blake drain (silastic tube)
Number of subjects: 150
Study 23575759 — intervention group
Group type: COMPARATOR
Intervention: Conventional mediastinal tube
Number of subjects: 150
Study 21616989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound-field amplification (SFA) devices
Number of subjects: 147
Study 21616989 — intervention group
Group type: COMPARATOR
Intervention: No sound-field amplification (SFA) devices
Number of subjects: 147
Study 18804218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive design
Number of subjects: 156
Study 18804218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 18804218 — intervention group
Group type: COMPARATOR
Intervention: Active control with known side effect
Number of subjects: 156
Study 16505865 — intervention group
Group type: EXPERIMENTAL
Intervention: Course in coping with depression
Number of subjects: 155
Study 16505865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 15523542 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 21
Study 15523542 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 21
Study 11259887 — intervention group
Group type: EXPERIMENTAL
Intervention: Guedel-type airway
Number of subjects: 30
Study 11259887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 30
Study 9298518 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day
Number of subjects: 191
Study 9298518 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 191
Study 8296751 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow balloon deflation
Number of subjects: 157
Study 8296751 — intervention group
Group type: COMPARATOR
Intervention: Fast balloon deflation
Number of subjects: 157
Study 3140995 — intervention group
Group type: EXPERIMENTAL
Intervention: megavoltage photon irradiation
Number of subjects: 14
Study 3140995 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclotron-generated fast neutrons
Number of subjects: 14
Study 3140995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 31088421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-augmented 'Trampoline' programme
Number of subjects: 420
Study 31088421 — intervention group
Group type: COMPARATOR
Intervention: Standard 'Trampoline' programme
Number of subjects: 420
Study 26231584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 31
Study 26231584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neonatal feeding (ENF)
Number of subjects: 24992
Study 23677862 — intervention group
Group type: COMPARATOR
Intervention: No early neonatal feeding
Number of subjects: 24992
Study 23677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived inability to suckle normally after birth
Number of subjects: 24992
Study 20701024 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily, one hour before sleep (group A)
Number of subjects: 33
Study 20701024 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily, one hour before sleep (group B)
Number of subjects: 33
Study 20701024 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 33
Study 18470755 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough QT/QTc study as per ICH E14 guidance
Number of subjects: 0
Study 16639731 — intervention group
Group type: COMPARATOR
Intervention: FAC (5-fluorouracil 1000 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 78
Study 16639731 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC followed by high-dose chemotherapy (HDCT) with autologous stem cell support (ASCS) (high-dose cyclophosphamide 5250 mg/m2, etoposide 1200 mg/m2, cisplatin 165 mg/m2)
Number of subjects: 78
Study 12631092 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (CHr) group
Number of subjects: 197
Study 12631092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin saturation (TSAT) group
Number of subjects: 197
Study 10722178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 12
Study 10722178 — intervention group
Group type: COMPARATOR
Intervention: Control session (sham depletion)
Number of subjects: 12
Study 8908525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (Group 1, n = 48)
Number of subjects: 141
Study 8908525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg daily for the first 10 days of a 21-day cycle with an oral contraceptive containing 2 mg cyproterone acetate (Group 2, n = 65)
Number of subjects: 141
Study 8908525 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100-200 mg daily) (Group 3, n = 12)
Number of subjects: 141
Study 8908525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily) (Group 4, n = 16)
Number of subjects: 141
Study 8908525 — intervention group
Group type: COMPARATOR
Intervention: Low-dose combined oral contraceptive (Group 1)
Number of subjects: 141
Study 8908525 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (Group 2)
Number of subjects: 141
Study 8908525 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (Group 4)
Number of subjects: 141
Study 8908525 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (Group 3)
Number of subjects: 141
Study 8908525 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study 1916651 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 24
Study 1916651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6761087 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with 200-mg clotrimazole suppositories
Number of subjects: 63
Study 6761087 — intervention group
Group type: COMPARATOR
Intervention: 7-day treatment with 100-mg clotrimazole suppositories
Number of subjects: 63
Study 6761087 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with miconazole or clotrimazole
Number of subjects: 63
Study 31072272 — intervention group
Group type: COMPARATOR
Intervention: MJ
Number of subjects: 30
Study 31072272 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ+SJ
Number of subjects: 30
Study 31072272 — intervention group
Group type: COMPARATOR
Intervention: AAS-MJ
Number of subjects: 30
Study 31072272 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS-MJ+SJ
Number of subjects: 30
Study 31060740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (10 mg ambrisentan + 40 mg tadalafil)
Number of subjects: 112
Study 31060740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (5 mg/20 mg)
Number of subjects: 112
Study 31060740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (5 mg/40 mg)
Number of subjects: 112
Study 31060740 — intervention group
Group type: COMPARATOR
Intervention: Reference monotherapies (Ambrisentan and Tadalafil)
Number of subjects: 112
Study 26893457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral robotic priming combined with the task-oriented approach
Number of subjects: 31
Study 26893457 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented approach alone
Number of subjects: 31
Study 26847016 — intervention group
Group type: EXPERIMENTAL
Intervention: Home DLMOs
Number of subjects: 32
Study 24265330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 50
Study 24265330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 50
Study 21074887 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+DSME
Number of subjects: 234
Study 21074887 — intervention group
Group type: COMPARATOR
Intervention: DSME alone
Number of subjects: 234
Study 19811168 — intervention group
Group type: EXPERIMENTAL
Intervention: Isabel (web-based decision support system)
Number of subjects: 117
Study 19811168 — intervention group
Group type: COMPARATOR
Intervention: Not using Isabel (control group)
Number of subjects: 117
Study 17826034 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) including family members
Number of subjects: 19
Study 17826034 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) directed solely at patients
Number of subjects: 19
Study 17826034 — intervention group
Group type: COMPARATOR
Intervention: Standard care or non-specific interventions
Number of subjects: 19
Study 15179645 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS)
Number of subjects: 9
Study 15179645 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study 11440277 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg tid subcutaneously for a maximum of 36 months)
Number of subjects: 18
Study 11440277 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18
Study 11440277 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study 9932217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day structured treatment and teaching programme (DTTP) for intensified insulin therapy
Number of subjects: 94
Study 7829634 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (Humatrope, Eli Lilly; 0.074 mg/kg, sc, 3 times/week; n = 9)
Number of subjects: 20
Study 7829634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study 7829634 — intervention group
Group type: COMPARATOR
Intervention: GH and Placebo
Number of subjects: 20
Study 2574986 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.1 mg kg‐1
Number of subjects: 24
Study 2574986 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural somatostatin 3 mg
Number of subjects: 24
Study 2574986 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 24
Study 764996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of acetone-inactivated and dried typhoid vaccine
Number of subjects: 35000
Study 764996 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of acetone-inactivated and dried typhoid vaccine
Number of subjects: 35000
Study 764996 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (Control)
Number of subjects: 35000
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: NTEP cultivars
Number of subjects: 20
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: R. solani
Number of subjects: 20
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: R. zeae
Number of subjects: 20
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes with improved resistance
Number of subjects: 20
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effects with pathogen
Number of subjects: 20
Study 31841100 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between R. solani and R. zeae disease severity
Number of subjects: 20
Study 31126528 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP50
Number of subjects: 648
Study 31126528 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CEOP70
Number of subjects: 648
Study 31126528 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CEOP90
Number of subjects: 648
Study 28651960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry culture
Number of subjects: 297
Study 28651960 — intervention group
Group type: COMPARATOR
Intervention: Humidified culture
Number of subjects: 297
Study 26250834 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet NIPPV
Number of subjects: 40
Study 26250834 — intervention group
Group type: COMPARATOR
Intervention: Mask NIPPV
Number of subjects: 40
Study 22633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MED)
Number of subjects: 3232
Study 22633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MDS)
Number of subjects: 3232
Study 22633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean style-dietary pattern score (MSDPS)
Number of subjects: 3232
Study 21350423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin and basic treatment (trental and group B vitamins)
Number of subjects: 94
Study 21350423 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 94
Study 21350423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 94
Study 21350423 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (metipred) as an add-on in pulse-treatment regime
Number of subjects: 94
Study 21350423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin, trental, group B vitamins and corticosteroids
Number of subjects: 94
Study 19118069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 900 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21
Study 19118069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 800 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21
Study 19118069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (various doses)
Number of subjects: 21
Study 19118069 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21
Study 17019548 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-vasopressin (AVP) (0.04-0.20 Umin(‐1), n=13)
Number of subjects: 23
Study 17019548 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) (0.1-2.8 microg kg(‐1)min(‐1), n=10)
Number of subjects: 23
Study 17019548 — intervention group
Group type: COMPARATOR
Intervention: Both groups (AVP and NE)
Number of subjects: 23
Study 17019548 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 23
Study 12562446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 243
Study 12562446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 243
Study 12562446 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 243
Study 10686246 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention (mailing with brochure and follow-up phone call)
Number of subjects: 594
Study 10686246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no outreach intervention)
Number of subjects: 594
Study 9406673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus and impaired glucose tolerance
Number of subjects: 2875
Study 9406673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia and hypertension
Number of subjects: 2875
Study 8458365 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (group A)
Number of subjects: 30
Study 8458365 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 30
Study 4025956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet trial
Number of subjects: 43
Study 4025956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet manipulation
Number of subjects: 43
Study 4025956 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind challenges
Number of subjects: 43
Study 4025956 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine provoking challenges
Number of subjects: 43
Study 29530257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback + Audience Feedback + Cognitive Review (CP + VF + AF + CR)
Number of subjects: 140
Study 29530257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback + Cognitive Review (CP + VF + CR)
Number of subjects: 140
Study 29530257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback only (CP + VF)
Number of subjects: 140
Study 29530257 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study 27488392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training, 4 sessions over 4 consecutive days during a 7-day detoxification program
Number of subjects: 83
Study 27488392 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control group), 4 sessions over 4 consecutive days during a 7-day detoxification program
Number of subjects: 83
Study 27488392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 83
Study 27488392 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Bias Modification (CBM) training and Sham training (control)
Number of subjects: 83
Study 23911604 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli 83972
Number of subjects: 4